RYR2 and catecholaminergic polymorphic ventricular tachycardia: For instance, a number of studies indicate that treatment with flecainide, a drug which is known to suppress arrhythmias in catecholaminergic polymorphic ventricular tachycardia (CPVT) caused by mutations in the RyR2, is also effective in suppressing arrhythmias in animal models and patients with ACM [31,33,141].